Legal & General Group Plc Takes $47.42 Million Position in Insulet Corporation $PODD

Legal & General Group Plc purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) in the second quarter, Holdings Channel.com reports. The fund purchased 311,452 shares of the medical instruments supplier’s stock, valued at approximately $47,419,000.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Insulet during the second quarter worth $1,018,582,000. State Street Corp lifted its stake in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after purchasing an additional 65,317 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Insulet by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after purchasing an additional 41,019 shares during the period. Invesco Ltd. grew its holdings in shares of Insulet by 10.5% during the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after purchasing an additional 141,167 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.36% of the stock is currently owned by insiders.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
• Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert

Insulet Stock Performance

NASDAQ PODD opened at $145.13 on Friday. The company has a market cap of $10.06 billion, a P/E ratio of 27.13, a P/E/G ratio of 1.13 and a beta of 1.10. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The stock has a 50-day moving average of $154.46 and a two-hundred day moving average of $181.15. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PODD shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Insulet in a report on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 price objective on the stock. Wells Fargo & Company lowered shares of Insulet from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $255.00 to $144.00 in a research note on Wednesday, August 5th. BTIG Research downgraded shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Raymond James Financial reissued an “outperform” rating and issued a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Finally, Canaccord Genuity Group decreased their price objective on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $195.40.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.